Impact of the Crisis on the Pharmaceutical Market in the Czech Republic and Hungary

• Autorzy: Markéta Lőrinczy
• Języki publikacji: EN

Abstrakty

EN

The pharmaceutical industry is one of the industries being most influenced by political changes. It is an industry which can both help and - without strict regulations - can also harm people. "Big pharma", as the biggest players on the pharmaceutical market are often named, is going through changes and it needs to react to the global economy demands, healthcare reforms, educated consumers and new diseases. Firms are preparing new, country-specific strategies and models to be able to take advantage of any new opportunities the given market should offer. (original abstract)

Słowa kluczowe

EN

Economic crisis; Pharmaceutical industry; Pharmaceutical market; Legal regulations

PL

Kryzys gospodarczy; Przemysł farmaceutyczny; Rynek farmaceutyczny; Regulacje prawne

• Czasopismo: Forum Scientiae Oeconomia
• Rocznik: 2013
• Tom: 1
• Numer: nr 2 Crisis in Europe: Effects in Economy
• Strony: 21--33

Twórcy

autor

Markéta Lőrinczy

• Mendel University of Agriculture and Forestry Brno, Czech Republic

Bibliografia

• 1. Bolt, T. (2012), The financial crisis in Europe: The perfect pharmaceutical storm, available at: http://healthscope.apcoforum.com/the-perfect-pharmaceutical-storm/ (accessed September 2013).
• 2. Boncz, I., Boncz, I., Nagy, J., Sebestyén, A., Kőrösi, L. (2004), Financing of health care services in Hungary, The European Journal of Health Economics, Vol. 5 No. 3, pp. 252-258.
• 3. Borbás, I. , Borbás, I., Mihalicza, P., Ajtonyi, Z., Lux L., Szirmai, L. (2011), Hungarian Health System Scan, Vol. 4 No. 1.
• 4. CBI Market Survey (2010), The pharmaceutical products market in Hungary, available at: http://www.cbi.eu/system/files/marketintel/2010_-_pharmaceutical_products_-_Hungary.pdf (accessed October 2012).
• 5. Czech Invest (2012), Inflow of foreign direct investment, available at: http://www.czechinvest.org/data/files/fs-02-inf low-of-fdi-66-en.pdf (accessed December 2012).
• 6. Davidova, J., Praznovcova L, Stasby Lundborg, C. (2008), Pricing and reimbursement of pharmaceuticals, in: the Czech Republic and Sweden, Pharmacy World and Science, Vol. 30 No. 2, pp. 57-64.
• 7. Dušek, O. (2009), Farmaceutický průmysl ve světě - geografické aspekty (Pharmaceutical industry in the world - geographical aspects), available at: http://theses.cz/id/b5htck/downloadPraceContent_adipIdno_10499 (accessed November 2012).
• 8. EC European Commission (2012), Impact of the economic crisis on key sectors of the EU - the case of the manufacturing and construction industries, available at: http://ec.europa.eu/enterprise/newsroom/cf/_getdocument.cfm?doc_id=5633 (accessed October 2013).
• 9. Espicom (2012), The pharmaceutical market: Hungary, available at: http://www.espicom.com/hungary-pharmaceutical-market (accessed October 2012).
• 10. FMR Fast Market Research (2012), Czech Republic pharmaceuticals & healthcare report Q4 2012, available at: http://www.fastmr.com/prod/499748_czech_republic_pharmaceuticals_healthcare_report.aspx (accessed December 2012).
• 11. GBI Market Research (2012), Emerging pharmaceutical market - Czech republic - Planned healthcare reform plans forecast to slow growt rates, available at: http://www.marketresearch.com/GBI-Research-v3759/Emerging-Pharmaceutical-Czech-Republic-Planned-6871115/ (accessed February 2013).
• 12. Gulácsi, L., Dávid T., Dózsa Cs. (2002), Pricing and reimbursement of drugs and medical devices in Hungary, The European Journal of Health Economics, Vol. 3 No. 4, pp. 271-278.
• 13. Hall, D. (2009), Healtcare: rejection of privatisationand patient fees in Central Europe, available at: http://www.psiru.org/reports/healthcare-rejection-privatisation-and-patient-fees-central-europe (accessed December 2012).
• 14. Healy, J., McKee, M. (1997), Health sector reform in central and eastern Europe: the professional dimension, Helath Policy and Planning, Vol.12 No. 4, pp. 286-295.
• 15. Hren, R. (2013), Impact of the pharma economic act on diffusion of innovation and reduction of costs in the Hungarian prescription drug market (2007-2010), Value in Health Regional Issues, Vol. 2 No. 2, pp. 290-299.
• 16. Embassy of Hungary in London (2006), Hungary: The logica choice, available at: http://www.mfa.gov.hu/kulkepviselet/UK/en/en_Bilateralis/hita_fdi.htm (accessed October 2012).
• 17. IHS (2012), Value of Czech pharmaceutical market falls 0.21% Y/Y in 2011, available at: http://www.ihs.com/products/global-insight/industry-economicreport.aspx?id=1065966192 (accessed December 2012).
• 18. Jablonski, F. (2007), The Hungarian pharmaceutical industry is highly sophisticated, available at: http://www.process-worldwide.com/measurement_and_control_automation/software/pcs/articles/296468/ (accessed October 2012).
• 19. Kanavos, P., Schurer, W., Vogler, S. (2011), The pharmaceutical distribution chain in the European, available at: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/structimpact_pharmaprices_032011_en.pdf (accessed October 2012).
• 20. Kazakov, R. (2007), Pricing and reimbursement policies in new EU accession countries. Journal of Generic Medicine, Vol. 4 No. 4, pp. 249-258.
• 21. Kiss, K. (2012), New trends in the Hungarian pharmaceutical industry, available at: http://h2onlinehu.wordpress.com/2012/01/19/new-trends-in-the-hungarian-pharmaceutical-industry/ (accessed 12 March 2013).
• 22. Law office Marečková (2012), Pharmaceuticals in the Czech Republic: medicinal products,medical devices, food suplements, cosmetics, available at: http://www.pharmaceuticals-czech.com/ (accessed December 2012).
• 23. Lengyel, B., Cadil, V. (2009), Innovation policy challanges in transition countries: foreign business R&D in the Czech Republic and Hungary, Transition Studies Review, Vol. 16 No. 1, pp. 174-188.
• 24. Lickens, K. et al. (2012), Hungary pharma report 2012, available at: http://issuu.com/focusreports/docs/hungary_pharm_2012 (accessed October 2012).
• 25. MCE Managament Centre Europe (2012), New opportunities and strategies in the pharmaceutical industry, available at: http://www.mce-ama.com/executiveissue-38-pharma-industry-2012/ (accessed November 2012).
• 26. Menčík, T. (2012), Farmaceutické společnosti, available at: http://www.cyrrus.cz/uploads/PDF/Analyza_Farmaceuticke_spolecnosti.pdf (accessed 12 December 2012).
• 27. Peto, F., Quintero Villa J.F., Szathmáry B. (2011), Changing winds in the Hungarian pharmaceutical market: Analysis of the changes in the regulatory framework, available at: http://www20.gencat.cat/docs/economia/80_ACCO/Documents/Arxius/Tesines BGSE/08.pharmaceutical_market_hungary. pdf (accessed 2 December 2013).
• 28. PMR (2011), Generic drug market in Central Europe will grow by 6% per annum between 2011 and 2013, available at: http://www.pmrpublications.com/press-releases/237/generic-drug-market-in-central-europe-will-grow-by-6-per-annum-between-2011-and-2013 (accessed October 2012).
• 29. PMR (2012), Hungary: market news. Central Europe Pharma News, Vol. 3 (62), pp. 8-10.
• 30. PwC (2011), Introducing the pharma 2020 Series, available at: http://www.pwc.com/gx/en/pharma-life-sciences/pdf/introducing-the-pharma-2020-seriesjuly-2011.pdf (accessed 3 February 2013).
• 31. Rusek, V. (2002), Historie farmaceutické výroby v Čechách a na Moravě, available at: http://cfs-cls.cz.gold.globenet.cz/files/sekce_lekarenstvi/Historie_farmaceuticke_vyroby3.pdf (accessed 5 December 2012).
• 32. Sass, M. (2004), FDI in Hungary: the first mover's advantage and disadvantage, available at: https://www.econstor.eu/dspace/bitstream/10419/44839/1/390945560.pdf (accessed September 2012).
• 33. SÚKL (2008), State institute for drug control, available at http://www.sukl.eu/sukl/legislation-of-the-czech-republic (accessed November 2012).
• 34. SÚKL (2012), Státní ústav pro kontrolu léčiv, available at: www.sukl.cz (accessed November 2012).
• 35. Vaněček, J. (2005), Pharmaceuticals and biotechnology in the Czech, available at: http://www.czelo.cz/dokums_raw/biotechnology_in_Czech.pdf (accessed 2 March 2013).
• 36. Vogler, S. et al. (2010), Generics promotion - analyzing differences between the hospital and out-patient sectors, available at: http://whocc.goeg.at/Literaturliste/dokumente/posters/EAHP_Poster_OHP30.pdf (accessed 26 February 2013).